Cancer 2003: Vol 98 Index

29 Pages·2003·6.7 MB·English

Subject Index—Volume 98
No. 1, July 1, pp. 1-214 No. 8, October 15, pp. 1555-1778
No. 2, July 15, pp. 215-436 No. 9, November 1, pp. 1779-2000
No. 3, August 1, pp. 437-660 No. 9, November 1, Supplement, pp. 2001-2082
No. 4, August 15, pp. 661-884 No. 10, November 15, pp. 2083-2306
No. 5, September 1, pp. 885-1104 No. 11, December 1, pp. 2307-2538
No. 6, September 15, pp. 1105-1330 No. 12, December 15, pp. 2539-2742
No. 7, October 1, pp. 1331-1554
A sequential interleukin 3 and granulocyte-macrophage-col-
ony stimulating factor in, 2410
Acquired immunodeficiency syndrome
fatigue and, 1786
Burkitt lymphoma in, chemotherapy for, 1196
\ngiogenesis. See also Vascular endothelial growth factor
Hodgkin disease in, population-based patterns of, 300
in breast cancer, endocrine therapy efficacy and, 2125
Kaposi sarcoma in, highly active antiretroviral therapy and,
inhibition of in breast cancer, trastuzumab and paclitaxel for,
2440
Acute leukemia. See Leukemia 1377
Adenocarcinoma. See also specific sites and types Angiogenic factors, circulating, monitoring of, in dendritic cell-
DARPP-32 in, 1547 based immunotherapy, 2291
free interferon-a/f receptors in circulation in, 2730 \ngiosarcoma
Adolescents. See also Children antiangiogenetic therapy for, with pioglitazone, rofecoxib, and
neuroblastoma in, 349 trofosfamide, 225]
\drenal suppression, megestrol acetate-related, in children, 397 of scalp, 1716
African Americans. See also Race/ethnicity \ntiangiogenetic therapy, for angiosarcoma, with pioglitazone,
brain tumor survival in, 603 rofecoxib, and trofosfamide, 2251
breast cancer survival in, 894, 908 Antibiotics, for febrile neutropenia requiring hospitalization
psychosocial factors in, 1299 1039
endometrial cancer outcome in, vs. in whites, 176 \nticoagulation, prophylactic, in central nervous system lym-
mammographic breast density in, 590 phoma, 1239
in oncology, ways to increase, 2736 (letter Antiemesis, prophylactic palonosetron for, 2473
XRCC3 polymorphism in, lung cancer risk and, 1701 \ntihypertensives, breast cancer and, 1334 (editorial), 1504
Agnogenic myeloid metaplasia, interferon for, 100 \ntiretroviral therapy, Kaposi sarcoma and, 2440
JCC Cancer Staging Manual, classification of isolated tumor Anxiety, in stem cell transplantation, music therapy for, 2723
ceils in 274) Aplastic anemia
Alaska Natives. See also Race/ethnicity infections in, 86
cancer rates among, 1262 sequential interleukin 3 and granulocyte-macrophage
Alemtuzumab
stimulating factor in, 2410
for chronic lymphocytic leukemia, 2657
\po2l in hematologic disorders 158
for chronic lymphoproliferative disorders, 773
Ara-( . See Cytosine arabinoside
\lpha-fetoprotein, in germ cell tumors, salvage surgery and,
Arm
1635
complications in, from axillary/sentinel node biopsy, in breast
Alternative medicine, clinical oncologists’ attitudes toward, in
cancer, 690
Japan, 2302 (letter
lymphedema of
American Indians. See also Race/ethnicity
laser therapy for, 1114
cancer rates among, 1262
in long-term breast cancer survivors, 679
American Joint Committee on Cancer Staging Manual, classifica
\romatase inhibitors, adjuvant, 1779 (editorial
tion of isolated tumor cells in, 2741
\sp835 mutations, in FLT3 gene, in acute promyelocytic leuke-
Amphotericin B, with caspofungin, for invasive aspergillosis, 292
Anastrozole, for breast cancer mia, 1206
vs. fulvestrant, 229 \sparaginase, PEG, for multiple myeloma, 94
with/without tamoxifen vs. tamoxifen alone, 1802 \spergillosis, caspofungin with liposomal amphotericin B for
Androgen receptors, in breast cancer, 703 Q9
\nemia \strocytoma
aplastic of spinal cord, 554 i
infections in, 86 tenascin-C in, prognosis and, 2430
bmiv CANCER December 15, 2003 / Volume 98 / Number 12
ATAC clinical trial, 1802 Book reviews
Autologous stem cell transplantation. See Stem cell transplanta- Cancer Medicine 6 (Kufe et al.), 2511
tion Cognitive Behavior Therapy for People with Cancer (Moorey &
Greer), 212
B Head and Neck Cancer: Emerging Perspectives (Ensley, Gut-
kind, Jacobs, & Lippman), 1160
Barrett esophagus Hormones, Genes, and Cancer (Henderson, Ponder & Ross),
hiatal hernia and, 940
251]
reflux and, 940
Mesothelioma (Robinson & Chahinian), 213
Basal cell carcinoma, superficial radiotherapy for, 2708
Brachytherapy. See also Radiation therapy
Basement membrane, loss of, in ovarian cancer, 2607 for prostate cancer
B-cell lymphoma. See Lymphoma
late genitourinary/ gastrointestinal toxicity and, 949
Bcl-2
Patterns of Care study of, 1987
in basal cell carcinoma, prognosis and, 2708
Brain metastasis
in breast cancer, in primary tumor and metastatic nodes,
in esophageal cancer, 1925
prognosis and, 2554
in neuroblastoma, 155
in nonsmall cell lung cancer, prognosis and, 135
in prostate cancer, 363
Behavioral therapy, in melanoma, 854
in thyroid cancer, 356
Benign prostatic hyperplasia, prostate cancer risk and, 1727
Brain tumors
B. microglobulin, in mantle cell lymphoma, prognosis and, 2630
desmoplastic medulloblastoma, in nevoid basal cell carci-
Bikunin gene expression, in ovarian cancer, prognosis and, 424
noma syndrome, 618
Biliary tract cancer, H. pylori infection and, 656 (letter)
glioblastoma
3i0psy
long-term survival in, 1745
core needle, in prostate cancer, as predictor of PSA recurrence
salvage therapy for, 2678
in, 2344
tenascin-C in, prognosis and, 2430
lymph node
glioma, low-grade pediatric, outcome in, 1243
in breast cancer, short-term morbidity of upper limb after,
medulloblastoma, dietetic intervention in, 1014
690
in ductal carcinoma in situ, 2083 (editorial) multiple primaries and, 562
nongerminomatous malignant germ cell, 369
Bisphosphonates, for osteolytic bone metastases, 1318
oligodendrogliomas, COX-2 in, prognosis and, 1465
Bladder cancer. See also Transitional cell carcinoma
cathepsin B in, 262 supratentorial primitive neuroectodermal, dietetic interven-
CD9 in, prognosis and, 1649 tion in, 1014
survival in, racial differences in, 603
with extravesical extension, postoperative natural history of,
tenascin-C in, prognosis and, 2430
955
fibroblast growth factor receptor 3 mutations in, 73 ( BRCAI mutations
gemcitabine and docetaxel for, 1863 in breast cancer, 1327 (letter)
genetic alterations in laser-capture—microdissected stroma lymph node metastasis and tumor size correlation and,
adjacent to, 1830 1569
heat shock proteins in, 970 in non-Jewish Spanish-Americans, 597
motility-related protein-1 in, prognosis and, 1649 Breast
after primary transitional cell carcinoma of upper urinary magnetic resonance imaging of, frequency of “probably be-
tract, 1620 nign” interpretations in, 377
urokinase-type plasminogen activator in, 1995 (letter) mammographic density of, racial differences in, 590
Bladder toxicity, of brachytherapy, in prostate cancer, 949 Breast cancer
Blast crisis, in chronic myelogenous leukemia, sudden onset of, adjuvant chemotherapy for
81 in older women, 1141
Bleeding, rectal, after brachytherapy for prostate cancer, 949 risk-benefit analysis for, 1150
Bleomycin, for Hodgkin disease, 978 anastrozole with/without tamoxifen vs. tamoxifen alone for,
with radiotherapy, 2393 1802
Body mass index. See Obesity androgen receptors in, 703
Bombesin, cytotoxic analogues of, for gastric cancer, 1401 antihypertensives and, 1334 (editorial), 1504
Bone marrow failure, sequential interleukin 3 and granulocyte- Bcl-2 in, in primary tumor and metastatic nodes, prognosis
macrophage-colony stimulating factor in, 2410 and, 2554
Bone marrow transplantation. See also Stem cell transplantation biology of, 1327 (letter)
for breast cancer, candidemia and, 25 bone marrow transplantation for, candidemia and, 25
music therapy in, 2723 bone metastases in, zoledronic acid vs. pamidronate diso-
Bone metastasis dium for, 1735
bisphosphonates and radiotherapy for, 1318 BRCAI mutations in, 1327 (letter)
in breast cancer, zoledronic acid vs. pamidronate disodium lymph node metastasis and tumor size correlation and,
for, 1735 1569
in multiple myeloma, zoledronic acid vs. pamidronate diso- in non-Jewish Spanish-Americans, 597
dium for, 1735 breast-conserving therapy for
osteolytic, bisphosphonates and radiotherapy for, 1318 eligibility for, routine mammography and, 918
in renal cell carcinoma, zoledronic acid for, 962 vs. mastectomy, for early-stage disease, 697
Subject Index—Volume 98 bmv
positive margins and ipsilateral recurrence in, prognosis regional recurrence in, prognosis and, 2144
and, 2512 (letter) screening for
regional recurrence after, prognosis and, 2144, 2145 breast density on, racial differences in, 590
routine mammography and, 918 in initial vs. recurrent disease, 1596
candidemia in, 25 in older women, primary physicians’ role in, 1811
coagulopathy in, 1578 primary physicians’ role in, 1811
docetaxel and pegylated liposomal doxorubicin for, 610 routine, disease stage and eligibility for conservative treat-
ductal carcinoma in situ ment and, 918
androgen receptors in, 703 tumor size and death rate and, 2114
occult micrometastasis in, 2083 (editorial), 2105 sentinel/axillary lymph node biopsy in, short-term morbidity
risk of, exercise and, 2161 of upper limb after, 690
ductal lavage in, diagnostic sensitivity of, 2170 sentinel nodes in, intraoperative immunofluorescent evalua-
early-onset, immunohistochemical biomarkers and HER-2/ tion of, 1562
neu gene amplification in, in Korean v. white woman, Size+ Node method of predicting outcome in, 2133
1587 in smokers, lung cancer after, 1457
early-stage stage at presentation of, routine mammography and, 918
long-term outcome of, 679 survival in
mastectomy vs. breast conservation therapy for, 697 psychosocial factors in, 1299
in elderly, adjuvant chemotherapy for, 1141 racial disparities in, 894, 908
elderly survivors of, favorable cardiac risk in, 2 syndecan-1 in, prognosis and, 474
exatecan mesylate for, 900 TFAP2C in, prognosis and, 18
filgastrim prophylaxis in, risk model for, 222 TOP1 in, prognosis and, 18
fulvestrant vs. anastrozole for, 229 trastuzumab and paclitaxel for, for angiogenesis inhibition
HER-2/neu in, utility of testing for, 2547 377
histologic grade of, racial differences in, 908 tumor size and lymph node status in, prognosis and, 2133
hormone replacement therapy and, 1552 (letter) vascular endothelial growth factor in, therapeutic efficacy
withdrawal of, short-term biologic response to, 2539 and, 2125
intraductal, in younger vs. older women, 1102 (letter) Vinorelbine palliation for, 1325 (lettet
isolated supraclavicular recurrence in, 11 Breast conservation therapy
low fat/high-fiber diet in prevention of, 1782 (editorial), 1870 eligibility for, routine mammography and, 918
lymph node biopsy in vs. mastectomy, tor early stage disease, 697
in ductal carcinoma in situ, 2083 (editorial) positive margins and ipsilateral recurrence in, prognosis and,
2512 (letter)
short-term morbidity of upper limb after, 690
regional recurrence after, prognosis and, 2145
lymph node metastasis in
for routine mammography and, 918
Bcl-2 and p53 in, prognosis and, 2554
t t o Breast implants, after prophylactic mastectomy, reoperation for,
in nonsentinel nodes,
2152
mastectomy for
B reslow depth, melanoma signs and symptoms and, 344
vs. breast conservation therapy, for early stage cancer, 697
Bromodeoxyuridine, with radiotherapy, for central nervous sys-
ductal lavage in, diagnostic sensitivity of, 2170
tem lymphoma, 1021
lymphedema after, laser therapy for, 1114
Burkitt lymphoma, HIV-related, chemotherapy for, 1196
preoperative MRI in, 468
prophylactic, reoperation after, 2152
skin-sparing, 2316 C
method of detection of, in initial vs. recurrent disease, 1596 c -ABL, in ovarian cancer, 758
NCOA3 in, prognosis and, 18 ( ‘alpain 6, in leiomyosarcoma, 1029
nutritional strategies for prevention of, 1782 (editorial), 1870 ( ‘analicular stenosis, docetaxel and, 504
p21“! up-regulation and p34“? hyperphosphorylation in ( ‘ancer, incidence/ prevalence of, among American Indians and
chemosensitivity and, 1123 Alaska Natives, 1262
p53 in, in primary tumor and metastatic nodes, prognosis -apecitabine, for nonsmall cell lung cancer, with docetaxel, 1918
and, 2554 varboplatin
in pregnancy, 1055 for nonsmall cell lung cancer
pregnancy after, survival and, 1131 vs. MIC/MVP, 542
preoperative MRI in, 468 in patients 70 years, 779
preoperative radiofrequency ablation of, 1369 for prostate cancer, 269, 1842
after “probably benign” interpretations on MRI, 377 with immunotherapy, 2592
prognosis in, psychosocial factors in, racial differences in, ‘ardiac disease, reduced risk for, in elderly breast cancer survi-
1299 vors, 2
radiotherapy for cardiac ransplantation, esophageal cancer after, mediastinal
with isolated supraclavicular recurrence, 11 irradiation for, 2738
lung cancer after, 1331 (editorial), 1362, 1457 career development, in gynecologic cancer, 2075
vs. mastectomy, in early stage disease, 697 ‘aspofungin, with liposomal amphotericin B, for invasive as-
routine mammography and, 918 pergillosis, 292
thyroid cancer after, 1309 ( ‘atechol-O-methyltransferase, genetic polymorphisms of, in fa-
utilization rate for, 1977 milial prostate cancer, 1411
bmvi CANCER December 15, 2003 / Volume 98 / Number 12
Cathepsin B, in bladder cancer, 262 for Hodgkin disease, 2393
CD4*°CD25° regulatory T cells, in gastrointestinal cancer, 1089 for nonsinonasal neuroendocrine head and neck cancer, 2322
CD9, in bladder cancer, prognosis and, 1649 Chemotherapy
CD30/CD30L, in hematologic disorders, 458 for acute lymphoblastic leukemia, in adult, 1337
CD33, in acute myeloid leukemia, 2095 anemia in
CD40/CD40L, in hematologic disorders, 458 erythropoietin-a for, 1072
CD86, in acute myeloid leukemia and myelodysplastic syn- fatigue and, 198, 1786
drome, 1681 for breast cancer, 229, 900
CDKN2A, in familial atypical multiple-mode melanoma-pancre- adjuvant chemotherapy for, 1150
atic carcinoma syndrome, 798 candidemia and, 25
Cefepime, for febrile neutropenia requiring hospitalization, 1039 in older women, 1141
Central nervous system lymphoma responsiveness to, erbB2 overexpression and, 1123
bromodeoxyuridine with radiation therapy for, 1021 vascular endothelial growth factor and, 2125
thromboembolism in, 1239 for Burkitt lymphoma, in HIV infection, 1196
Central nervous system metastases, in neuroblastoma, 155 for cervical cancer, with concurrent radiotherapy and hyper-
Cerebral metastasis thermia, 277
in esophageal cancer, 1925 for choroid metastasis, 1232
in neuroblastoma, 155 for chronic myelogenous leukemia, 888
in prostate cancer, 363 clinical trials for. See Clinical trials
in thyroid cancer, 356 for colorectal cancer, toxicity of, body mass index and, 484
for cutaneous T-cell lymphoma, 993
Cervical cancer
behavioral factors in, 2009 for diffuse large B-cell lymphoma, in elderly, 2651
biology of, 2064 drug approval for, ethical issues in, 215 (editorial)
endocrine therapy efficacy and, 2125
chemoprevention of, 2044
cyclin-dependent kinase inhibitors in, 1880 for Ewing sarcoma, long-term complications of, 2687
for extraocular retinoblastoma, 1292
decision science and, 2003
for extremity soft tissue sarcoma, 1483
diagnosis of, behavioral factors in, 2009
for gastric cancer, histologic tumor regression grade in, 1521
fertility-sparing surgery for, 2052
for gastrointestinal stromal tumors, 2693
human papillomavirus and, 2064
for glioblastoma, salvage therapy for, 2678
hysterectomy for, 2052
for hepatic metastases in colorectal cancer, 320
imaging in, 2028
for hepatoblastoma, 668
computed tomography in, 2039
for Hodgkin disease, 978
optical technology in, 2009
for low-grade gliomas, in children, 1243 »
international conference on, 2001
for lung cancer, clinical trials for, cost-effectiveness of
invasive, treatment innovations for, 2052
for lymphoma, 983
locally advanced, concurrent radiotherapy, chemotherapy,
for melanoma, 1355
and hyperthermia for, 277
mucositis in, 1531
matriptasel/MT-SP1 in, prognosis and, 1898
nausea and vomiting in
nursing role in prevention and treatment of
assessment tool for, 645
obesity and, 814
palonosetron prophylaxis for, 2473
pelvic exenteration for, 2052 for neuroblastoma, 2488
quality of life and, behavioral factors in, 2009
for nongerminomatous intracranial malignant germ cell tu
radiation therapy for, 2052
mors, 369
screening for
for non-Hodgkin lymphoma, febrile neutropenia in, hospital-
behavioral factors in, 2009
ization for, 2402
nurse's role in, 2009
for nonsmall cell lung cancer, 542, 1707, 1918
sentinel node dissection in, 2514 (letter) in patients >70 years, 779
sexual rehabilitation in, 2009 for osteosarcoma, 832, 2447
surrogate endpoint biomarkers for, 2044 of head and neck, 1670
rADG-15 in, prognosis and, 1898 response to, P-glycoprotein and, 581
telomerase in, 2064 sensitivity to, reduced folate carrier protein and, 1947
vaccines for, 2044, 2064 for ovarian cancer, 1664
venous thrombosis in, 1514 for prostate cancer, 269, 1603, 1627, 1842, 1855, 2088 (edito-
Cervical fluorophores, in cervical cancer, 2015 rial), 2192
Cervix, imaging of, 2028 with immunotherapy, 2592
computed tomography in, 2039 in metronomic therapy, 1643
optical technology in, 2009 with radiotherapy. See Chemoradiation
Chemoradiation for renal cell carcinoma, 61, 1837
anemia in, erythropoietin-a for, 1072 for rhabdomyosarcoma, in adults, 571
for central nervous system lymphoma, 1021 for soft tissue sarcoma, 2693
for cervical cancer, 2052 for thymic cancer, 926
venous thrombosis and, 1514 Children. See also specific pediatric cancers
for esophageal cancer, with locoregional spread, 2177 diffuse lymphoblastic lymphoma in, outcome in, 1283
Subject Index—Volume 98 bmvii
low-grade gliomas in, outcome in, 1243 translation initiation factor elF-2a, 1080
megestrol acetate for, adrenal suppression and, 397 treatment-related toxicity in, body mass index and, 484
Cholangiocarcinoma ‘omplementary and alternative medicine, clinical oncologists’
hilar, patterns of initial recurrence in, 1689 attitudes toward, in Japan, 2302 (letter
serum MUCS5AC mucin in, prognosis and, 1438 ‘omputed tomography
Chordomas, skull base/non-skull base, nuclear pleomorphism in cervical cancer, 2039
in, prognosis and, 1934 in lung cancer screening, smoking abstinence after, 2495
Choroid metastasis, clinical features and treatment of, 1232 onjunctival MALT lymphoma, radiotherapy for, 865
Chromate workers, respiratory tract chromium accumulation in, ore needle biopsy, in prostate cancer, as predictor of PSA
2420 recurrence in, 2344
Chromogranin A, serial measuremeni of, for gastrinomas, 249 ‘oronary heart disease, reduced risk for, in elderly breast cancer
Chronic hepatitis, estrogen receptor- in, clinicopathologic cor- survivors, 2
‘orrespondence, 430, 872, 1101, 1325, 1995, 2302,
relates of, 529
Chronic leukemia. See Leukemia 2512, 2736
‘orticosteroids. See also Prednisone
Chronic lymphoproliferative disorders, alemtuzumab for, 7
with megestrol acetate, in children, 397
Chronic myeloproliferative disorders, interferon for, 100
‘ortisol, megestrol acetate-related decrease in, in children, :
Chronotherapy, 861 (letter)
‘ost analysis, for cervical cancer, 2003
Cigarette smoking
in cancer patients, cessation strategies for, 632 COX-2
in oligodendrogliomas, prognosis and, 1465
lung cancer in breast cancer survivors and, 1457
in Ovarian cancer, 2607
after lung cancer screening, 2495
tumor vascularity and, 1423
oropharyngeal cancer and, UGT1A10 polymorphisms and, 872
(OX-2 inhibitors, in hepatocellular carcinoma prevention, 661
Cirrhosis, estrogen receptor-f in, clinicopathologic correlates of, craniofacial surgery, for skull base tumors, 1179
529 ryotherapy, for hepatic metastases, in colorectal cancer, 320
Cisplatin ‘utaneous angiosarcoma, of scalp, 1716
for advanced seminoma, 745 ‘utaneous T-cell lymphoma
for esophageal cancer, with radiotherapy, 2177 juvenile-onset mycosis fungoides, outcome in, 2282
for extraocular retinoblastoma, 1292 pegylated liposomal doxorubicin for, 993 2
for nonsmall cell lung cancer, 128, 1707 Cyclin D1, in early-onset breast cancer, in Korean v. white
vs. gemcitabine-carboplatin, 542 woman, 1587
for paranasal sinus cancer, 2214 Cyclin-dependent kinase inhibitors
for thymic cancer, 926 in cervical cancer, prognosis and, 1880
c-KIT, in ovarian cancer, 758 in leiomyosarcoma, 1029
Clear cell ependymoma, 2232 Cyclooxygenase-2
Clinical trials in oligodendrogliomas, prognosis and, 1465
ATAC, 1802 in ovarian cancer, 2607
cost-effectiveness of, 1491 tumor vascularity and, 1423
disclosure of “new findings” to candidates for, 885 Cyclooxygenase-2 inhibitors, in hepatocellular carcinoma pre-
ethical issues in, 215 (editorial) vention, 661
expectations of benefit from, 166 Cyclophosphamide
for lung cancer, cost-effectiveness of, 1491 for breast cancer, responsiveness to, erbB2 overexpression
for renal cell carcinoma, response assessment classification and, 1123
in, 1611 for Burkitt lymphoma, in HIV infection, 1196
c-Met expression, in tall cell variant papillary thyroid cancer, for extraocular retinoblastoma, 1292
for non-Hodgkin lymphoma, hospitalization for febrile neu-
1386
C-myc, in medulloblastoma, 841 tropenia and, 2402
Coagulopathy, in breast cancer, 1578 for prostate cancer, 1603
Cognitive-behavioral interventions, in melanoma, 854 in metronomic therapy, 1643
Colon cancer. See Colorectal cancer CYP19, genetic polymorphisms of, in familial prostate cancer,
Colonic epithelial tumors, translation initiation factor elF-2ca in, 1411
Cytosine arabinoside
1080
for Burkitt lymphoma, in HIV infection, 1196
Colorectal cancer
for chronic myelogenous leukemia, 888
care prevalence of, in United States, 1253
for lymphoma, 983
CD4°CD25°~ regulatory T cells in, 1089
female long-term survivors of, quality of life and social net-
works of, 1749 D
hepatic metastasis in, hepatic cryotherapy and regional che- Dab-2, in ovarian cancer, 2607
motherapy for, 320 Darbepotin-a, for fatigue, 1786
hereditary nonpolyposis, endometrial cancer surveillance in DARPP-32, in adenocarcinoma, 1547
women at risk for, 1772 (letter) Decision science, cervical cancer and, 2003
hMLH1 in, high-resolution methylation analysis of, 1540 Decitabine, for chronic myelogenous leukemia, 522
reirradiation and hyperthermia for, 1759 Deep vein thrombosis
synchronous, microsatellite instability in, 48 in breast cancer, 1578
bmviii CANCER December 15, 2003 / Volume 98 / Number 12
in central nervous system lymphoma, 1239 elF-2a, in melanocytic and colonic epithelial tumors, 1080
in cervical cancer, 1514 Elderly
Dendritic cell-based immunotherapy, monitoring of circulating breast cancer in
angiogenic factors in, 2291 adjuvant chemotherapy for, 1141
Denmark, prognostic implications of HER-2 overexpression in screening for, primary care physicians’ role in, 1811
ovarian cancer in, 66 breast cancer survivors, favorable cardiac risk in, 2
Depigmentation, of skin, imatinib mesylate-induced, 2483 chronic myelogenous leukemia in, imatinib mesylate for,
Depression prognosis and, 1105
fatigue and, 198 diffuse large B-cell lymphoma in, doxorubicin-based chemo-
in stem cell transplantation, music therapy for, 2723 therapy for, 2651
Des-gamma-carboxy prothrombin index, in hepatocellular car- endometrial cancer in, aggressiveness of, 2368
cinoma, prognosis and, 2671 mammography in, primary physicians’ role in, 1811
Desmoplastic medulloblastoma, in nevoid basal cell carcinoma non-Hodgkin lymphoma in, 1188
syndrome, 618 nonsmall cell lung cancer in, carboplatin-paclitaxel for, 779
Dexamethasone, for prostate cancer, in metronomic therapy, Emesis, chemotherapy-induced
1643 assessment tool for, 645
Diaphanous 3, in leiomyosarcoma, 1029 palonosetron prophylaxis for, 2473
Diet. See also Nutritional support Emotional distress. See also Quality of life
low-fat/high-fiber, in breast cancer prevention, 1782 (edito- in autologous stem cell transplantation, music therapy for,
rial), 1870 2723
rectal mucosal cell proliferation and, 1161 in melanoma, cognitive-behavioral interventions for, 854
Diethylstilbestrol, for prostate cancer, 1603 Endocrine cancers, poorly differentiated, genetic alterations in,
Diffuse large B-cell lymphoma 1273
doxorubicin-based chemotherapy for, in elderly, 2651 Endocrine therapy
prognosis of, in younger patients, 516 for breast cancer, vascular endothelial growth factor and, 2125
Diffuse lymphoblastic lymphoma, pediatric, outcome in, for prostate cancer, number-needed-to-treat analysis o f, 2351
Disabled-2, in ovarian cancer, 2607 End of life care, palliative care in, oncologists’ attitudes toward,
DNA mismatch repair defects, 2091 (editorial), 2199
2502
Docetaxel
Endometrial cancer
for advanced cancer, with pegylated liposomal doxorubicin, in elderly, aggressiveness of, 2368
610 hMLH1 in, high-resolution methylation analysis of, 1540
nasolacrimal duct obstruction and, 504 outcome in, racial differences in, 176
for nonsmall cell lung cancer, with capecitabine, 1918
steroid receptor coactivators and corepressors in, 2207
for prostate cancer, 1627, 1855 surveillance for, in women at risk for hereditary nonpolyposis
with immunotherapy, 92 colorectal cancer, 1772 (letter)
Dopamine and cyclic adenosine 3’,5’-monophosphate-regulated
Endometrial hyperplasia, steroid receptor coactivators and core-
phosphoprotein, in adenocarcinoma, 1547
pressors in, 2207
Doublecortin, in leiomyosarcoma, 1029
Endometrial polyps, tamoxifen-related, K-ras mutations in, 1890
Doxorubicin
Endometrial thickening, secondary ultrasonographic, after ta-
for Burkitt lymphoma, in HIV infection, 1196
moxifen, 431 (letter)
for diffuse large B-cell lymphoma, in elderly, 2651
Endometriosis, ovarian cancer and, 1658
for extraocular retinoblastoma, 1292
Endoscopic management, of transitional cell carcinoma of up-
for Hodgkin disease, 978
per urinary tract, 55
for neuroblastoma, 2488
Endostatin, in hepatocellular carcinoma, tumor vascularity and,
for non-Hodgkin lymphoma, hospitalization for febrile neu-
1101 (letter)
tropenia and, 2402
Enteral nutrition. See Nutritional support
pegylated liposomal
Ependymoma, clear cell, 2232
for cutaneous T-cell lymphoma, 993
Epidermal growth factor, neuropilin-1 and, in pancreatic cancer,
with docetaxel, for advanced cancer, 610
for thymic cancer, 926 720
Epiphora, docetaxel and, 504
Drug approval. See also Clinical trials
Epoetin-a, for anemic patients receiving chemoradiation, 1072
ethical issues in, 215 (editorial)
Epstein-Barr virus DNA, in nasopharyngeal cancer, prognosis
Ductal carcinoma in situ
and, 288
androgen receptors in, 703
occult micrometastasis in, 2083 (editorial), 2105 Epstein-Barr virus latent membrane protein 1 gene, in mucosal
risk of, exercise and, 2161 recurrent nasopharyngeal carcinoma, 2385
erbB2, in breast cancer, chemosensitivity and, 1123
Ductal lavage, in breast cancer, diagnostic sensitivity of, 2170
DX-8951f, for breast cancer, 900 Errata, 659, 1104, 2000, 2743
Erythropoietin
for cervical cancer, venous thrombosis and, 1514
E
for fatigue, 1786
Echinococcal infection, in cancer prevention, 1998 (letter) Esophageal cancer
Ecteinascidin 743, for recurrent osteosarcoma, 832 body size and, 940
Editorials, 1, 215, 219, 1779, 1782, 2083, 2088, 2091 CD4°CD25° regulatory T cells in, 1089
Educational level, survival and, 1497 cerebral metastasis in, 1925
Subject Index—Volume 98 bmix
chemoradiation for, 2177 FGFR3, in urine sediment DNA, in bladder cancer, 737
hiatal hernia and, 940 FHIT protein, in poorly differentiated endocrine carcinomas
mediastinal irradiation for, after heart transplant, 2738 (lette1 1273
reflux and, 940 Fiber, dietary
sentinel node mapping in, 932 breast cancer risk and, 1782 (editorial), 1870
‘sophagus, Barrett rectal mucosal cell proliferation and, 1161
hiatal hernia and, 940 Fibroblast growth factor receptor 3 mutations, in urine sediment
reflux and, 940 DNA, in bladder cancer, 737
‘ssential thrombocythemia, interferon for, 100 Fibroblast growth factor receptor 4 single nucleotide polymot
Estradiol, dietary fat/fiber and, 1870 phism, in soft tissue sarcoma, prognosis and, 2245
istramustine Field cancerization, in upper urinary tract, 1620
for prostate cancer, 269, 1842, 2192 Fifth phacomatosis, desmoplastic medulloblastoma in, 618
with immunotherapy, 2592 Filgastrim, prophylactic, for breast cancer, risk model for, 222
for renal cell cancer, 1837 FLT3 gene, Asp835 mutations in, in acute promyelocytic leuke
‘strogen, cardioprotective effects of, in elderly breast cancer mia, 1206
survivors, 2 -Fluoro-2-deoxyglucose positron emission tomography
sstrogen receptor(s) in nasopharyngeal cancer, 283
a-type, genetic polymorphisms of, in familial prostate cancer, in recurrent oral squamous cell carcinoma, 2257
1411 Fluorophores, cervical, 2015
B-type, in liver cancer, clinicopathologic correlates of, 529 5-Fluorouracil, for breast cancer, responsiveness to, erbB2 ove!
in breast cancer, after withdrawal of hormone replacement expression and, 1123
therapy, 2539 FMS-like tyrosine kinase 3 gene, Asp835 mutations in, in acute
in early-onset breast cancer, in Korean v. white woman, 1587 promyelocytic leukemia, 1206
endometriosis-associated ovarian cancer and, 1658 Fractures, pathologic, in long-term Ewing sarcoma survivors
strogen receptor antagonists, for breast cancer, 229 2687
strogen replacement therapy Fulvestrant, vs. anastrozole, for breast cancer, 229
breast cancer and, 1552 (letter) ungal infections, in aplastic anemia, 86
withdrawal of in breast cancer, short-term biologic response Fusarium infection, in hematologic malignancies, prognostic
to, 2 factors in, 315
thical issues, 1555
in drug approval, 215 (editorial) G
toposide
for Burkitt lymphoma, in HIV infection, 1196 Gallbladder cancer, patterns of initial recurrence in, 1689
for extraocular retinoblastoma, 1292 Ganglioneuroblastoma, nodular, prognostic subsets in, 22
for prostate cancer, 269, 2192 Gastric cancer
for thymic cancer, 926 body mass index and, 940
wing sarcoma, long-term survivors of, complications in, 2687 CD4° CD25 regulatory T cells in, 1089
xatecan mesylate, for breast cancer, 900 chemotherapy for, histologic tumor regression grade in, 1521
hiatal hernia and, 940
Xercise
ductal carcinoma in situ risk and, 2161 reflux and, 940
for fatigue, 1786 REG expression in, prognosis and, 1394
Extraadrenal pheochromocytoma, high-dose -metaiodoben- targeted cytotoxic somatostatin/bombesin analogues fot
zylguanidine for, 239 140]
Extremity, upper trefoil factor 1 transcript in, 2184
complications in, from axillary/sentinel node biopsy, in breast Gastrin, serial measurement of, for gastrinomas, 249
cancer, 690 Gastrinomas
lymphedema of immunophenotype of, 1967
laser therapy for, 1114 tumor burden changes in, serial chromogranin A and gastrin
in long-term breast cancer survivors, 679 measurements for, 249
Extremity sarcoma, pleomorphic, myoid differentiation in, prog- Gastroesophageal reflux disease, esophageal/ gastric cancer risk
and, 940
nosis and, 805
Gastrointestinal cancer
CD4° CD25 regulatory T cells in, 1089
poorly differentiated endocrine, genetic alterations in, 1273
Familial atypical multiple-mode melanoma-—pancreatic carci- Gastrointestinal stromal tumors, temozolomide for, 2693
noma syndrome, phenotype in, 798 Gemcitabine
Familial sarcoma, 1947 for Hodgkin disease, 978
Fat, dietary, breast cancer risk and, 1782 (editorial), 1870 for nonsmall cell lung cancer, 128,
Fatigue vs. MIC/MVP, 542
evaluation and treatment of, 1786 plus oxaliplatin, 2664
psychologic distress and, 198 pulmonary toxicity of, 978
Febrile neutropenia, requiring hospitalization Gemtuzumab ozogamicin, for acute myeloid leukemia, 2095
in CHOP, CHOP-2, or CNOP chemotherapy, 2402 Germ cell tumors
imipenem and cefepime for, 1039 with elevated tumor markers, salvage surgery for, 1635
in non-Hodgkin lymphoma, 2402 nongerminomatous intracranial, 369
bmx CANCER December 15, 2003 / Volume 98 / Number 12
Gleason score, in prostate cancer, prognosis and, 2560 prevention of, cyclooxygenase-2 inhibitors in, 661
Glioblastoma serum endostatin in, tumor vascularity and, 1101 (leter)
long-term survival in, 1745 telomere length in, prognosis and, 110
salvage therapy for, 2678 Hepatoma-derived growth factor, in hepatocellular cancer,
tenascin-C in, prognosis and, 2430 prognosis and, 1444
Glioma, low-grade pediatric, outcome in, 1243 HER-2/neu
Glottic cancer, radiotherapy for, 765 in breast cancer, utility of testing for, 2547
Glucocorticoids. See also Prednisone in early-onset breast cancer, in Korean v. white woman, 1587
with megestrol acetate, in children, 397 in ovarian cancer, prognosis and, 66
Gorlin syndrome, desmoplastic medulloblastoma in, 618 Hereditary nonpolyposis colorectal cancer, endometrial cancer
Grantsmanship, in gynecologic cancer, 2075 surveillance in women at risk for, 1772 (letter)
Granulocyte—colony-stimulating factor Hernia, hiatal, esophageal/gastric cancer risk and, 940
with ifosfamide and mesna, for mesothelioma, 331 HERV-E, in prostate cancer, 187
for prostate cancer, with chemotherapy, 2592 Hiatal hernia, esophageal/ gastric cancer risk and, 940
Granulocyte-macrophage-colony stimulating factor, interleukin Highly active antiretroviral therapy, Kaposi sarcoma and, 2440
3 and, in bone marrow failure, 2410 Hilar cholangiocarcinoma, patterns of initial recurrence in, 1689
Gynecologic cancer investigator, career development of, 2075 Hippocratic tradition, 1555
Hispanics. See also Race/ethnicity
H BRCAI mutations in, 597
mammographic breast density in, 590
Head and neck cancer. See also specific types
XRCC3 polymorphism in, lung cancer risk and, 1701
nonsinonasal neuroendocrine, management of, 2322
HIV infection. See Human immunodeficiency virus infection
outcome in, educational level and, 1497
hMLH1, high-resolution methylation analysis of, in endometrial
pathologic vs. clinical lymph node staging in, 508
and colorectal cancer, 1540
radiotherapy for, racial factors in outcome of, 2467
hMLH1 promoter regulation, in ovarian cancer, 2199
recurrent, [" F|-2-fluorodeoxyglucose positron emission to-
Hodgkin disease. See also Hematologic malignancies; Lym-
mography in, 2257
phoma
UGTI1A10 polymorphisms in, 872
Head and neck osteosarcoma, National Cancer Data Base report ABVG regimen for, 978
chemoradiation for, 2393
on, 1670
HIV-related, population-based patterns of, 300
Heart disease, reduced risk for, in elderly breast cancer survivors,
recurrent, rituximab for, 310
)
Homoharringtonine, for chronic myelogenous leukemia, 888
Heart transplantation, esophageal cancer after, mediastinal irra
diation for, 2738 Hormonal therapy
Heat shock proteins, in bladder cancer, 970 for breast cancer, vascular endothelial growth factor and, 2125
Helicobacter pylori infection, benign and malignant biliary dis- for prostate cancer, number-needed-to-treat analysis of, 235]
ease and, 656 (letter Hormone receptors. See Estrogen receptor(s); Progesterone re-
Hemangioendothelioma, antiangiogenetic therapy for, with pio- ceptor(s
glitazone, rofecoxib and trofosfamide, 2251 Hormone replacement therapy
Hematologic disorders, tumor necrosis factor superfamily in, breast cancer and, 1552 (letter)
458 withdrawal of in breast cancer, short-term biologic response
Hematologic malignancies. See also specific sites and types to, 2539
aspergillosis in, caspofungin with liposomal amphotericin B Hormones, sex, dietary fat/fiber and, 1870
for, 292 Human chorionic gonadotropin, in germ cell tumors, salvage
Fusarium infection in, prognostic factors in, 315 surgery and, 1635
tumor necrosis factor superfamily in, 458 Human endogenous retrovirus E envelope genes, in prostate
Hepatic cryotherapy, for hepatic metastases, in colorectal can- cancer, 187
cer, 320 Human immunodeficiency virus infection
Hepatic metastases Burkitt lymphoma in, chemotherapy for, 1196
in colorectal cancer, hepatic cryotherapy and regional chemo- Hodgkin disease in, population-based patterns of, 300
therapy for, 320 Kaposi sarcoma in, highly active antiretroviral therapy and,
percutaneous radiofrequency ablation of, 2303 (letter) 2440
Hepatic transplantation, for hepatoblastoma, 668 tuman papillomavirus, cervical cancer and, 2064
Hepatitis, estrogen receptor-@ in, clinicopathologic correlates of, Human telomerase reverse transcriptase
229 in hepatocellular cancer, prognosis and, 110
Hepatoblastoma, current status of research and treatment in, in nonsmall cell lung cancer, prognosis and, 1008
668 Hydatid disease, in cancer prevention, 1998 (letter)
Hepatocellular carcinoma Hydrocortisone, with megestrol acetate, in children, 397
CD4°~ CD25" regulatory T cells in, 1089 Hypercoagulability, in breast cancer, 1578
des-gamma-carboxy prothrombin index in, prognosis and, Hyperthermia, 219 (editorial)
2671 for cervical cancer, with concurrent radiotherapy and chemo-
estrogen receptor-f in, clinicopathologic correlates of, 529 therapy, 277
hepatoma-derived growth factor in, prognosis and, 1444 for rectal cancer, 1759
osteopontin in, prognosis and, 119 Hyperuricemia, rasburicase for, 1048
percutaneous radiofrequency ablation therapy for, 433 (letter) Hypocortisolism, megestrol acetate-related, in children, 397
Subject Index—Volume 98 bmxi
Hypodiploidy, in acute lymphoblastic leukemia, prognosis and, J
20k
Japan, clinical oncologists’ attitudes toward complementary and
Hypopigmentation, of skin, imatinib mesylate-induced, 2483
alternative medicine in, 2302 (letter
Hysterectomy, for cervical cancer, 2052
K
I Kaposi sarcoma, AIDS-related, highly active antiretroviral ther-
apy and, 2440
Ifosfamide
Ketoconazole, for prostate cancer, 1855
for Burkitt lymphoma, in HIV infection, 1196
for extraocular retinoblastoma, 1292 Ki-67
in breast cancer, after withdrawal of hormone replacement
with mesna and granulocyte—colony-stimulating factor, for
therapy, 2539
mesothelioma, 331
in endometrial hyperplasia/carcinoma, steroid receptor coac-
for nonsmall cell lung cancer, vs. gemcitabine-carboplatin,
tivators and corepressors and, 2207
542
Koreans, early-onset breast cancer in, immunohistochemical bi-
for paranasal sinus cancer, 2214
omarkers and HER-2/neu gene amplification in, 1587
Imatinib mesylate
K-ras mutations, in tamoxifen-related endometrial polyps, 1890
for chronic myelogenous leukemia, 437, 888, 1776 (letter)
age-prognosis relationship and, 1105
in children, 2643 L
chromosomal abnormalities in Ph-negative metaphases Lacrimal duct obstruction, docetaxel and, 504
and, 1905 Lacrimal glands, MALT lymphoma of, radiotherapy for, 865
after interferon-a therapy, 1430 I aser desorption/ionization time-of-flight spectrometry, in
vs. interferon-a therapy, 2636 prostate cancer, for biomarker discovery, 2576
skin hypopigmentation and, 2483 Laser therapy, for postmastectomy lymphedema, 1114
3/1311_MIBG, for neuroblastoma, thyroid protection in, 389
atent membrane protein ] gene, in mucosal recurrent naso-
Imipenem, for febrile neutropenia requiring hospitalization, pharyngeal carcinoma, 2385
1039 atinos/ Latinas. See also Race/ethnicity
Immunization BRCAI mutations in, 597
for cervical cancer, 2044 mammographic breast density in, 590
with plasmid DNA vaccine, for melanoma, 144 XRCC3 polymorphism in, lung cancer risk and, 1701
Immunofluorescence, in intraoperative evaluation of sentinel egal issues, 1555
nodes, in breast cancer, 1562 eiomyosarcoma, differential gene expression in, 1029
Immunohistochemical biomarkers, in early-onset breast cancer, etters to editor, 430, 872, 1101, 1325, 1552, 1772 1995, 2302
in Korean v. white woman, 1587 20k 2, ate
Immunoradiometric assay, for thyroglobulin, vs. radioimmuno- eukemia. See also Hematologic malignancies
assay, 41 acute lymphoblastic
Immunotherapy in adults, biology and treatment of, 133
dendritic cell-based, monitoring of circulating angiogenic hypodiploidy in, prognosis and, 2715
factors in, 2291 soluble tumor necrosis factor in, prognosis and, 625
for prostate cancer, with chemotherapy, 2592 acute myeloid
for renal cell carcinoma, with nephrectomy, survival predic- gemtuzumab ozogamicin for, 2095
tion for, 2566 soluble CD86 in, prognosis and, 1681
Incidence, among American Indians and Alaska Natives, 1262 acute promyelocytic, Asp835 mutations in FLT3 gene in, 1206
Incremental cost-effectiveness ratio, for lung cancer, 1491] chronic lymphocytic
Infection control, for hospitalized SARS patient, 2739 alemtuzumab for, 773
Infections, in aplastic anemia, 86 for residual disease, 2657
Interferon-a, for chronic myelogenous leukemia, 437, 888, 2636 pulmonary complications in, 1912
Interferon, for chronic myeloproliferative disorders, 100 chronic myelogenous
Interferon-a/f receptors, in adenocarcinoma, 2730 biology of, 437
Interleukin-2, for renal cell carcinoma, with nephrectomy, sur- blast crisis in, sudden onset of, 81
vival prediction for, 2566 decitabine for, 522
Interleukin-3, granulocyte-macrophage-colony stimulating fac- diagnosis of, 437
tor and, in bone marrow failure, 2410 imatinib mesylate for, 437, 888, 1776 (letter
Interleukin-6, in Hodgkin disease, rituximab effects on, 310 age-prognosis relationship and, 1105
Interleukin-17B, in leiomyosarcoma, 1029 in children, 2643
International Conference on Cervical Cancer, 2001 chromosomal abnormalities in Ph-negative metaphases
International Neuroblastoma Pathology Classification, revision and, 1905
of, 227: after interferon-a, 1430
International Prognostic Index, for diffuse large B-cell lym- vs. interferon-a, 2636
phoma, in younger patients, 516 skin hypopigmentation and, 2483
3-lodobenzylguanidine, for neuroblastoma, thyroid protection interferon-a for
in, 389 with cytarabine and homoharringtonine, 888
Irinotecan, for renal cell carcinoma, 61 vs. imatinib mesylate, 2636
Isolated tumor cells, TNM classification of, 2741 imatinib mesylate after, 1430
bmxii CANCER December 15, 2003 / Volume 98 / Number 12
laboratory findings in, 4: Lymph node metastasis
prognosis of, 437 in breast cancer
in elderly, 1105 Bcl-2 and p53 in, prognosis and, 2554
treatment of, 437, 1105 in nonsentinel nodes, 2307
prolymphocytic, alemtuzumab for, 773 tumor size and, 1569
tumor necrosis factor in, 458 mechanisms of, 413
Liposomal amphotericin B, with caspofungin, for invasive as- in melanoma, vascular endothelial growth factor-C and, 789
pergillosis, 292 in nonsmall cell lung cancer, vascular endothelial growth fac-
Liver cancer. See also Hepatocellular carcinoma tor-C and, 1217
estrogen receptor-f in, clinicopathologic correlates of, 529 in papillary microcarcinoma of thyroid, 31
Liver metastases in thyroid cancer, 712
in colorectal cancer, hepatic cryotherapy and regional chemo- Lymphoblastic lymphoma, pediatric, outcome in, 1283
therapy for, 320 Lymphoma. See also Hematologic malignancies
percutaneous radiofrequency ablation of, 2303 (letter) Burkitt, HIV-related, chemotherapy for, 1196
Liver transplantation, for hepatoblastoma, 668 central nervous system
LMP-1, in mucosal recurrent nasopharyngeal carcinoma, 2385 bromodeoxyuridine with radiation therapy for, 1021
Loss of heterozygosity, in poorly differentiated endocrine carci- thromboembolism in, 1239
nomas, 1273 cutaneous T-cell
Low-fat diet, in breast cancer prevention, 1782 (editorial), 1870 juvenile-onset mycosis fungoides, outcome in, 2282
Lumpectomy pegylated liposomal doxorubicin for, 993
eligibility for, routine mammography and, 918 diffuse large B-cell
vs. mastectomy, for early stage cancer, 697 doxorubicin-based chemotherapy for, in elderly, 2651
positive margins and ipsilateral recurrence in, prognosis and, prognosis of, in younger patients, 516
2512 (letter) in elderly, 1188
regional recurrence after, prognosis and, 2145 febrile neutropenia in, hospitalization for, 2402
Lung cancer high-risk aggressive, chemotherapy and autografting for, 983
in breast cancer Hodgkin. See Hodgkin disease
after radiotherapy, 1331 (editorial), 1362, 1457 large B-cell, prognosis of, in younger patients, 516
in smokers, 1457 lymphoblastic, pediatric, outcome in, 1283
in chromate workers, 2420 MALT, of ocular adnexa, radiotherapy for, 865
clinical trials for, cost-effectiveness of, 1491 mantle cell
CT screening for, smoking abstinence after, 2495 autologous stem cell transplant for, outcome of, 2630
nonsmall cell B. microglobulin in, prognosis and, 2630
bcl-2 in, prognosis and, 135 tumor necrosis factor in, 458
carboplatin-paclitaxel for, in patients 70 years, 779
gemcitabine, paclitaxel, and cisplatin induction for, 1707
gemcitabine and cisplatin for, 128
M
gemcitabine-carboplatin vs. MIC/MVP for, 542
gemcitabine for, 337 Magnetic resonance imaging
human telomerase reverse transcriptase MRNA in, progno- of breast
sis and, 1008 frequency of “probably benign” interpretations in, 377
with tumor of2 cm or less, management and prognosis of, preoperative, 468
350 for nasopharyngeal cancer, vs. ‘°-fluoro-2-deoxyglucose
vascular endothelial growth factor-C in, nodal metastasis positron emission tomography, 283
and, 1217 Magnetic resonance imaging-guided brachytherapy, for prostate
TSLC1 in, clinical/prognostic significance of, 1002 cancer, genitourinary/ gastrointestinal toxicity of, 949
XRCC3 polymorphism and, in minority populations, 1701 Malignant hemangioendothelioma, antiangiogenetic therapy
Lung disorders, in chronic lymphocytic leukemia, 1912 for, with pioglitazone, rofecoxib and trofosfamide,
Lymphedema 2251
in long-term breast cancer survivors, 679 Malignant melanoma. See Melanoma
postmastectomy, laser therapy for, 1114 Malignant mesothelioma. See Mesothelioma
Lymph node(s) Malignant pheochromocytoma, high-dose ' ‘!_metaiodobenzyl-
retroperitoneal, dissection of, for sex-cord stromal tumors, guanidine for, 239
753 Malignant pleural effusion, in chronic lymphocytic leukemia,
sentinel 1912
biopsy of. See Lymph node biopsy MALT lymphoma, of ocular adnexa, radiotherapy for, 865
in breast cancer, intraoperative immunofluorescent evalu- Mammography
ation of, 1562 breast density on, racia! differences in, 590
dissection of, in cervical cancer, 2514 (letter) in initial vs. recurrent disease, 1596
mapping of, in esophageal cancer, 932 in older women, primary physicians’ role in, 1811
Lymph node biopsy primary physicians’ role in, 1811
axillary/sentinel node, in breast cancer, short-term morbidity routine, disease stage and eligibility for conservative treat-
of upper limb after, 690 ment and, 918
sentinel node, in ductal carcinoma in situ, 2083 (editorial) tumor size and death rate and, 2114